To the full analysis
ImmunityBio stock: growth
IBRXImmunityBio reported $113.29M in revenue for fiscal 2025, up 668.3% on the prior year, up 184.8% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
54.8%
per year from 2013 to 2025, per share 41.6%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2013 | |
|---|---|---|---|
| Revenue | 184.8% | 85.4% | 54.8% |
| Revenue per share | 139.0% | 67.2% | 41.6% |
| Earnings | no data | no data | no data |
| Earnings per share | no data | no data | no data |
| Free cash flow | no data | no data | no data |
| Free cash flow per share | no data | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2013 | $600K | −$2.05M | −$671K |
| 2014 | $641K | −$6.21M | −$5.65M |
| 2015 | $236K | −$236.88M | −$27.55M |
| 2016 | $44K | −$120.81M | −$45.15M |
| 2017 | $45K | −$96.42M | −$83.6M |
| 2018 | $47K | −$96.23M | −$76.48M |
| 2019 | $43K | −$65.79M | −$156.4M |
| 2020 | $605K | −$221.85M | −$173.39M |
| 2021 | $934K | −$346.79M | −$307.98M |
| 2022 | $240K | −$416.57M | −$415.67M |
| 2023 | $622K | −$583.2M | −$397.34M |
| 2024 | $14.75M | −$413.56M | −$398.12M |
| 2025 | $113.29M | −$351.4M | −$308.78M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 17 Oct 2026)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.